« Return to News | Awards & Advancement

Rosenberg joins Esperion Therapeutics as CMO

Monday, April 9, 2012 02:56 PM

Esperion Therapeutics, a Plythmouth, Michigan-based company that discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases, has appointed Noah Rosenberg, MD, as its chief medical officer.

Rosenberg will lead the Esperion clinical advisory board and will develop and manage the company's clinical programs. He will also manage the regulatory review process for the company's investigational therapies to prevent, treat and reverse cardiovascular and metabolic diseases. In addition, Rosenberg will play an instrumental role in corporate planning related to financing to support the ongoing development of Esperion's novel portfolio.

Rosenberg has held several senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the U.S. and globally at Pfizer, Sanofi-Aventis and Forest Laboratories. He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute (FRI), he led the successful in-licensing of the GK1-399 program and, until his departure, served as a standing member of the Joint Development Committee (JDC) with partner TransTech Pharma. Noah also coordinated the successful integration of the Forest cardiovascular and metabolism clinical development teams and managed the group through a highly productive period, helping to strengthen a pipeline that ultimately included compounds such as bystolic and azimilide. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.